FindTrial
Sign In

Effect of the administration of a single-dose of GnRH-a in the luteal phase on IVF-ET/ICSI-ET clinical outcomes-RCT

An assessor-blind, open-label, Randomized, Parallel-group study to evaluates the clinical pregnancy rate of single dose GnRH agonist administration on ICSI –ET /IVF-ET in GnRH antagonist ovarian stimulation protocol

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012397
Enrollment
Unknown
Registered
2017-08-17
Start date
2017-08-17
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

GnRHa group:GnRHa group receive two injections of GnRHa 0.1 mg s.c. on the day of ET and D3 after ET in addition to routine LPS
placebo group:placebo group receive two injections of placebo 0.1 mg s.c. on the day of ET and D3 after ET in addition to routine LPS

Sponsors

The 105th Hospital of People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. the GnRH antagonist protocol; 2. IVF or ICSI; 3. cycles of ART treatment less than 3 times; 4. Aged younger than 38 years old; 5. FSH less than 10mIU/ml, antral follicle count more than 6 or the number of oocytes recovered more than 3; 6. 250 ug of human recombinant HCG-triggered cycles; 7. BMI 19 kg/m2 to 28 kg/m2.

Exclusion criteria

Exclusion criteria: 1. endometriosis patients; 2. hydrosalpinx; 3. endometrial adhesion or Endometrial postoperative adhesion; 4. uterine malformation.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;live birth rate;—

Countries

China

Contacts

Public ContactHong Jiang

Reproductive Medicine Center, The 105th Hospital of PLA

jiangh105@sina.com+86 0551-65966361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026